RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sprint Bioscience Stock

Sprint Bioscience Net Income 2024

Sprint Bioscience Net Income

21.16 M SEK

Ticker

SPRINT.ST

ISIN

SE0006343745

WKN

A14NY2

In 2024, Sprint Bioscience's profit amounted to 21.16 M SEK, a -4,930.02% increase from the -438,000 SEK profit recorded in the previous year.

The Sprint Bioscience Net Income history

YEARNET INCOME (undefined SEK)
2025e105.78
2024e21.16
2023-0.44
2022-60.17
2021-25.08
2020-42.79
2019-21.54
2018-31.89
2017-10.66
20164.54
2015-15.5
2014-11.46
2013-4.39
2012-3.55

Sprint Bioscience Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Sprint Bioscience, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Sprint Bioscience from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Sprint Bioscience’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Sprint Bioscience. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Sprint Bioscience’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Sprint Bioscience’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Sprint Bioscience’s growth potential.

Sprint Bioscience Revenue, EBIT and net profit per share

DateSprint Bioscience RevenueSprint Bioscience EBITSprint Bioscience Net Income
2025e212.1 M SEK133.32 M SEK105.78 M SEK
2024e98.98 M SEK20.2 M SEK21.16 M SEK
202350.49 M SEK-845,000 SEK-438,000 SEK
202283,000 SEK-60.74 M SEK-60.17 M SEK
202135.11 M SEK-25.63 M SEK-25.08 M SEK
202016.89 M SEK-37.68 M SEK-42.79 M SEK
201933.54 M SEK-20.43 M SEK-21.54 M SEK
201817.94 M SEK-31.75 M SEK-31.89 M SEK
201723.97 M SEK-10.67 M SEK-10.66 M SEK
201634.99 M SEK4.57 M SEK4.54 M SEK
20157.73 M SEK-15.36 M SEK-15.5 M SEK
20140 SEK-11.26 M SEK-11.46 M SEK
20132.37 M SEK-4.16 M SEK-4.39 M SEK
20121.59 M SEK-5.24 M SEK-3.55 M SEK

Sprint Bioscience stock margins

The Sprint Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sprint Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sprint Bioscience.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Sprint Bioscience's sales revenue. A higher gross margin percentage indicates that the Sprint Bioscience retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Sprint Bioscience's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Sprint Bioscience's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Sprint Bioscience's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Sprint Bioscience. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Sprint Bioscience's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Sprint Bioscience Margin History

Sprint Bioscience Gross marginSprint Bioscience Profit marginSprint Bioscience EBIT marginSprint Bioscience Profit margin
2025e82.77 %62.86 %49.87 %
2024e82.77 %20.41 %21.37 %
202382.77 %-1.67 %-0.87 %
2022-15,478.31 %-73,180.72 %-72,493.98 %
202170.28 %-72.99 %-71.43 %
202038.06 %-223.13 %-253.43 %
201975.63 %-60.92 %-64.21 %
201841.89 %-177.03 %-177.82 %
201787.53 %-44.51 %-44.49 %
201698.8 %13.05 %12.98 %
2015102.69 %-198.75 %-200.61 %
201482.77 %0 %0 %
2013244.3 %-175.53 %-185.23 %
2012235.85 %-329.56 %-223.27 %

Sprint Bioscience Aktienanalyse

What does Sprint Bioscience do?

The Swedish company Sprint Bioscience AB is an innovative developer of drugs targeted for use in cancer. The company was founded in Stockholm in 2009 and has since worked with a strong focus on molecular research. Sprint Bioscience is a biotechnology company with the goal of developing drugs for various types of cancer. The company's focus is on so-called "trickster molecules" that can prevent tumor cells from taking up nutrients, ultimately leading to their death. The innovative business model of Sprint Bioscience is that they focus on the discovery and development of molecules, which they then sell to larger pharmaceutical companies that further develop and bring them to market. Sprint Bioscience has a wide range of molecular tools that allow for the identification, development, and optimization of cancer therapy drugs. The company aims to accelerate the discovery of new drugs in the field of oncology. Sprint Bioscience is divided into two business areas: discovery, which specializes in the identification and optimization of drugs for use in cancer, and development, which focuses on the preclinical development of drugs that are later further developed by larger pharmaceutical companies. The most well-known product of Sprint Bioscience is the molecule "SB-11285", a novel cancer therapeutic specifically developed for ovarian cancer. The molecule is intended to help destroy cancer cells by disrupting their cellular metabolism and depriving them of their energy source. Sprint Bioscience has also formed partnerships with other companies to exchange technologies and expertise. For example, there is a collaboration with Bayer to develop new oncology drugs. Overall, Sprint Bioscience has undergone significant development in recent years. The company has built strong expertise in the field of molecular research and effectively implemented its business model. Sprint Bioscience presents itself as a promising player in the biotechnology industry and has the potential to achieve further significant progress in the coming years. Sprint Bioscience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Sprint Bioscience's Profit Margins

The profit margins of Sprint Bioscience represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Sprint Bioscience's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Sprint Bioscience's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Sprint Bioscience's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Sprint Bioscience’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Sprint Bioscience stock

How much profit has Sprint Bioscience made this year?

Sprint Bioscience has made 21.16 M SEK this year.

How has the profit developed compared to last year?

The profit has increased by -4,930.02% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Sprint Bioscience publish its earnings?

Sprint Bioscience publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Sprint Bioscience?

The profits of Sprint Bioscience are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Sprint Bioscience?

You can learn more about the earnings of Sprint Bioscience by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Sprint Bioscience pay?

Over the past 12 months, Sprint Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sprint Bioscience is expected to pay a dividend of 0 SEK.

What is the dividend yield of Sprint Bioscience?

The current dividend yield of Sprint Bioscience is .

When does Sprint Bioscience pay dividends?

Sprint Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sprint Bioscience?

Sprint Bioscience paid dividends every year for the past 0 years.

What is the dividend of Sprint Bioscience?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sprint Bioscience located?

Sprint Bioscience is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sprint Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sprint Bioscience from 7/22/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/22/2024.

When did Sprint Bioscience pay the last dividend?

The last dividend was paid out on 7/22/2024.

What was the dividend of Sprint Bioscience in the year 2023?

In the year 2023, Sprint Bioscience distributed 0 SEK as dividends.

In which currency does Sprint Bioscience pay out the dividend?

The dividends of Sprint Bioscience are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sprint Bioscience

Our stock analysis for Sprint Bioscience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sprint Bioscience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.